Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC)

University of Aarhus

Status

Enrolling

Conditions

Liver Metastases

Pancreatic Neoplasm

Pancreatic Cancer

Treatments

Diagnostic Test: Preoperative MRI

Study type

Interventional

Funder types

Other

Identifiers

NCT05428358

MAGIPAC

Details and patient eligibility

About

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Full description

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
No liver metastases on CT
At least 18 years old and able to provide informed consent
Expected pancreatic ductal adenocarcinoma based on CT scan

Exclusion criteria

Metastatic disease
Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
Comorbidity rendering major surgery unfeasible (inoperable)
No informed consent
Unable to undergo MRI (Kidney insufficiency (eGFR < 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
MRI with liver-specific contrast performed during standard workup.